ICI’s Nolvadex
Executive Summary
Tamoxifen for the prevention of breast cancer is well tolerated in women at high risk for developing breast cancer, T.J. Powels, MD, Royal Marsden Hospital concluded in a presentation at the May 22 meeting of the American Society of Clinical Oncology. Because tamoxifen has demonstrated low toxicity, high compliance, and a lipid lowering profile in the 200-women pilot trial, a 10,000-patient multicenter trial is beginning enrollment in the U.K. and should be completed in the next two years, Powles said. Results of the pilot trial will be presented at the June 29 meeting of FDA's Oncologic Drugs Advisory Committee.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.